Evotec AG (NASDAQ:EVO) Given Consensus Rating of “Hold” by Analysts

Evotec AG (NASDAQ:EVO) has been assigned an average rating of “Hold” from the five ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $7.00.

Several research firms have commented on EVO. Berenberg Bank began coverage on Evotec in a report on Tuesday, February 3rd. They issued a “buy” rating on the stock. Wall Street Zen raised shares of Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a report on Monday, December 29th.

Institutional Trading of Evotec

Several institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new stake in shares of Evotec in the 4th quarter worth $40,000. Valeo Financial Advisors LLC purchased a new position in Evotec in the 2nd quarter worth about $43,000. BNP Paribas Financial Markets lifted its stake in Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after acquiring an additional 4,600 shares during the period. Bank of America Corp DE lifted its stake in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after acquiring an additional 9,289 shares during the period. Finally, Thrivent Financial for Lutherans purchased a new stake in shares of Evotec during the 3rd quarter valued at about $53,000. 5.81% of the stock is currently owned by hedge funds and other institutional investors.

Evotec Stock Down 0.3%

Shares of EVO opened at $3.40 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.12 and a quick ratio of 2.03. The business’s 50 day moving average price is $3.47 and its 200-day moving average price is $3.50. Evotec has a 52 week low of $2.84 and a 52 week high of $4.80.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.